Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Gains from Sales and Divestitures (2021 - 2025)

AVITA Medical (RCEL) has disclosed Gains from Sales and Divestitures for 4 consecutive years, with $109180.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Sales and Divestitures fell 26.49% year-over-year to $109180.0, compared with a TTM value of $109180.0 through Dec 2025, down 26.49%, and an annual FY2025 reading of $109180.0, down 26.49% over the prior year.
  • Gains from Sales and Divestitures was $109180.0 for Q4 2025 at AVITA Medical, roughly flat from $109180.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $235059.0 in Q4 2023 and bottomed at $14608.0 in Q1 2025.
  • Average Gains from Sales and Divestitures over 4 years is $105887.9, with a median of $105034.0 recorded in 2022.
  • The sharpest move saw Gains from Sales and Divestitures surged 194.99% in 2023, then crashed 41.8% in 2024.
  • Year by year, Gains from Sales and Divestitures stood at $132568.0 in 2022, then skyrocketed by 77.31% to $235059.0 in 2023, then crashed by 36.81% to $148532.0 in 2024, then dropped by 26.49% to $109180.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for RCEL at $109180.0 in Q4 2025, $109180.0 in Q3 2025, and $76724.0 in Q2 2025.